Nutlin

Nutlin 3
Names
	IUPAC name (±)-4-[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one
	Other names Nutlin
Identifiers
CAS Number	548472-68-0 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL191334 ;
PubChem CID	16755649;
UNII	53IA0V845C ;
	SMILES CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl;
Properties
Chemical formula	C30H30Cl2N4O4
Molar mass	581.49 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Nutlins are cis-imidazoline analogs which inhibit the interaction between mdm2 and tumor suppressor p53, and which were discovered by screening a chemical library by Vassilev et al. Nutlin-1, nutlin-2, and nutlin-3 were all identified in the same screen;^[1] however, Nutlin-3 is the compound most commonly used in anti-cancer studies.^[2] Nutlin small molecules occupy p53 binding pocket of MDM2 and effectively disrupt the p53–MDM2 interaction that leads to activation of the p53 pathway in p53 wild-type cells.^[3] Inhibiting the interaction between mdm2 and p53 stabilizes p53, and is thought to selectively induce a growth-inhibiting state called senescence in cancer cells. These compounds are therefore thought to work best on tumors that contain normal or "wild-type" p53.^{[citation needed]} Nutlin-3 has been shown to affect the production of p53 within minutes.^[4]

The more potent of the two enantiomers, nutlin-3a ((–)-nutlin-3), can be synthesized in a highly enantioselective fashion.^[5] Several derivatives of nutlin, such as RG7112 and RG7388 (Idasanutlin) have been developed and progressed into human studies.^[6] Imidazoline core based on the methoxyphenyl substituents also stabilizes p53.^[7]^[8]^[9]

References

↑ "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2". Science 303 (5659): 844–8. February 2004. doi:10.1126/science.1092472. PMID 14704432. Bibcode: 2004Sci...303..844V.
↑ "Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy". Annual Review of Pharmacology and Toxicology 49: 223–41. 2008. doi:10.1146/annurev.pharmtox.48.113006.094723. PMID 18834305.
↑ "Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy". Proceedings of the National Academy of Sciences of the United States of America 103 (6): 1888–93. February 2006. doi:10.1073/pnas.0507493103. PMID 16443686.
↑ "Mechanism-specific signatures for small-molecule p53 activators". Cell Cycle (Landes Bioscience) 10 (10): 1590–8. May 2011. doi:10.4161/cc.10.10.15519. PMID 21490429.
↑ "Catalytic, Enantioselective Synthesis of Stilbene cis-Diamines: A Concise Preparation of (-)-Nutlin-3, a Potent p53/MDM2 Inhibitor". Chemical Science 2 (6): 1076–1079. January 2011. doi:10.1039/C1SC00061F. PMID 22708054.
↑ "Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells". Cancers (Basel) 10 (11): 396. Nov 2018. doi:10.3390/cancers10110396. PMID 30352966.
↑ Bazanov, Daniil R.; Pervushin, Nikolay V.; Savin, Egor V.; Tsymliakov, Michael D.; Maksutova, Anita I.; Sosonyuk, Sergey E.; Kopeina, Gelina S.; Lozinskaya, Natalia A. (December 2021). "Sulfonamide derivatives of cis-imidazolines as potent p53-MDM2/MDMX protein-protein interaction inhibitors" (in en). Medicinal Chemistry Research 30 (12): 2216–2227. doi:10.1007/s00044-021-02802-w. ISSN 1054-2523. https://link.springer.com/10.1007/s00044-021-02802-w.
↑ Bazanov, Daniil R.; Pervushin, Nikolay V.; Savitskaya, Victoria Yu.; Anikina, Lada V.; Proskurnina, Marina V.; Lozinskaya, Natalia A.; Kopeina, Gelina S. (August 2019). "2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation" (in en). Bioorganic & Medicinal Chemistry Letters 29 (16): 2364–2368. doi:10.1016/j.bmcl.2019.06.007. PMID 31196710. https://linkinghub.elsevier.com/retrieve/pii/S0960894X19303749.
↑ Bazanov, Daniil R.; Pervushin, Nikolay V.; Savin, Egor V.; Tsymliakov, Michael D.; Maksutova, Anita I.; Savitskaya, Victoria Yu.; Sosonyuk, Sergey E.; Gracheva, Yulia A. et al. (2022-04-02). "Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core" (in en). Pharmaceuticals 15 (4): 444. doi:10.3390/ph15040444. ISSN 1424-8247. PMID 35455441.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Nutlin. Read more

[Nutlin-1] "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2". Science 303 (5659): 844–8. February 2004. doi:10.1126/science.1092472. PMID 14704432. Bibcode: 2004Sci...303..844V.

[annrev-2] "Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy". Annual Review of Pharmacology and Toxicology 49: 223–41. 2008. doi:10.1146/annurev.pharmtox.48.113006.094723. PMID 18834305.

[3] "Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy". Proceedings of the National Academy of Sciences of the United States of America 103 (6): 1888–93. February 2006. doi:10.1073/pnas.0507493103. PMID 16443686.

[Leeuwen_et_al.-4] "Mechanism-specific signatures for small-molecule p53 activators". Cell Cycle (Landes Bioscience) 10 (10): 1590–8. May 2011. doi:10.4161/cc.10.10.15519. PMID 21490429.

[5] "Catalytic, Enantioselective Synthesis of Stilbene cis-Diamines: A Concise Preparation of (-)-Nutlin-3, a Potent p53/MDM2 Inhibitor". Chemical Science 2 (6): 1076–1079. January 2011. doi:10.1039/C1SC00061F. PMID 22708054.

[6] "Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells". Cancers (Basel) 10 (11): 396. Nov 2018. doi:10.3390/cancers10110396. PMID 30352966.

[7] Bazanov, Daniil R.; Pervushin, Nikolay V.; Savin, Egor V.; Tsymliakov, Michael D.; Maksutova, Anita I.; Sosonyuk, Sergey E.; Kopeina, Gelina S.; Lozinskaya, Natalia A. (December 2021). "Sulfonamide derivatives of cis-imidazolines as potent p53-MDM2/MDMX protein-protein interaction inhibitors" (in en). Medicinal Chemistry Research 30 (12): 2216–2227. doi:10.1007/s00044-021-02802-w. ISSN 1054-2523. https://link.springer.com/10.1007/s00044-021-02802-w.

[8] Bazanov, Daniil R.; Pervushin, Nikolay V.; Savitskaya, Victoria Yu.; Anikina, Lada V.; Proskurnina, Marina V.; Lozinskaya, Natalia A.; Kopeina, Gelina S. (August 2019). "2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation" (in en). Bioorganic & Medicinal Chemistry Letters 29 (16): 2364–2368. doi:10.1016/j.bmcl.2019.06.007. PMID 31196710. https://linkinghub.elsevier.com/retrieve/pii/S0960894X19303749.

[9] Bazanov, Daniil R.; Pervushin, Nikolay V.; Savin, Egor V.; Tsymliakov, Michael D.; Maksutova, Anita I.; Savitskaya, Victoria Yu.; Sosonyuk, Sergey E.; Gracheva, Yulia A. et al. (2022-04-02). "Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core" (in en). Pharmaceuticals 15 (4): 444. doi:10.3390/ph15040444. ISSN 1424-8247. PMID 35455441.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

Nutlin

Topic: Chemistry

References